Cargando…

2111. Anidulafungin vs. Micafungin Treatment in Adult Patients with Candidemia: A Retrospective Study of Single-Center Experience

BACKGROUND: Candidemia is one of the fatal causes of nosocomial infection, requiring prompt recognition and treatment. Echinocandins are recommended for the treatment of invasive candidiasis and candidemia. Although similar clinical efficacy and safety are well known between caspofungin and micafung...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suh, Jinwoong, Yeon Kim, Jeong, Seung Chung, You, Lee, Hojin, Bean Kim, Sun, Kyung Yoon, Young, Wook Sohn, Jang, Ja Kim, Min, Hun Kim, Jong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809273/ http://dx.doi.org/10.1093/ofid/ofz360.1791

Ejemplares similares

Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
por: Suh, Jin Woong, et al.
Publicado: (2020)

1694. Predictors of Septic Shock in Adult Patients with Candidemia: A Single-Center Experience Over 13 Years
por: Woong Suh, Jin, et al.
Publicado: (2019)

1698. Epidemiology and Antifungal Susceptibility of Candidemia Among Adult Patients at a Tertiary Care Hospital in South Korea During an 8-Year Period
por: Hun Kim, Jong, et al.
Publicado: (2019)

Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex
por: Marx, Jana, et al.
Publicado: (2020)

375. Tolerability of Anidulafungin for Candidemia in Patients With Hepatic or Renal Dysfunction
por: Kim, Ji Young, et al.
Publicado: (2018)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)

1702. Prevalence and Risk Factors for Endogenous Fungal Endophthalmitis in Adult Patients with Candidemia at a Tertiary Care Hospital in South Korea Over 13 years
por: Hun Kim, Jong, et al.
Publicado: (2019)

Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
por: Kofla, G, et al.
Publicado: (2011)

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study
por: van der Geest, Patrick J., et al.
Publicado: (2016)

Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
por: Ruhnke, M, et al.
Publicado: (2011)

817. Caspofungin versus Anidulafungin in Patients with Candidemia: Retrospective Comparative Study
por: Elajez, Reem, et al.
Publicado: (2023)

Epidemiological Trends of Candidemia and the Impact of Adherence to the Candidemia Guideline: Six-Year Single-Center Experience
por: Kim, Jong Hun, et al.
Publicado: (2021)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature
por: Wilke, MH
Publicado: (2011)

In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against Four Candida auris Clades
por: Adnan, Awid, et al.
Publicado: (2023)

1499. Distribution and Clinical Implication of Isolation of Multidrug-Resistant Microorganisms in Patients with Intra-Abdominal Infections
por: Kyung Yoon, Young, et al.
Publicado: (2019)

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species
por: Tóth, Zoltán, et al.
Publicado: (2020)

Risk Factors for Candidemia as Compared with Patients with Negative Blood Cultures Placed on Empiric Micafungin
por: Carr, Amy, et al.
Publicado: (2017)

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
por: Roilides, Emmanuel, et al.
Publicado: (2020)

Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil
por: Vianna, Cid Manso de Mello, et al.
Publicado: (2023)

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum
por: Kovács, Renátó, et al.
Publicado: (2021)

Species Distribution of Candidemia and Their Susceptibility in a Single Japanese University Hospital: Prior Micafungin Use Affects the Appearance of Candida parapsilosis and Elevation of Micafungin MICs in Non-parapsilosis Candida Species
por: Sakamoto, Yasutaka, et al.
Publicado: (2021)

Evaluation of Fluconazole versus Echinocandins for Treatment of Candidemia Caused by Susceptible Common Candida Species: A Propensity Score Matching Analysis
por: Kim, Jong Hun, et al.
Publicado: (2023)

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
por: Kett, Daniel H, et al.
Publicado: (2011)

Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial
por: Mootsikapun, Piroon, et al.
Publicado: (2013)

Antiviral activity of micafungin against enterovirus 71
por: Kim, Chonsaeng, et al.
Publicado: (2016)

MIR2111-5 locus and shoot-accumulated mature miR2111 systemically enhance nodulation depending on HAR1 in Lotus japonicus
por: Okuma, Nao, et al.
Publicado: (2020)

Molecular and virulence characteristics of carbapenem-resistant Acinetobacter baumannii isolates: a prospective cohort study
por: Park, Seung Min, et al.
Publicado: (2023)

Gram-Negative Bacteria’s Outer Membrane Vesicles
por: Kim, Jeong Yeon, et al.
Publicado: (2023)

Clinical impact of COVID-19 in patients with carbapenem-resistant Acinetobacter baumannii bacteraemia
por: Kim, Jeong Yeon, et al.
Publicado: (2023)

Characteristics of Klebsiella pneumoniae Isolates from Stool Samples of Patients with Liver Abscess Caused by Hypervirulent K. pneumoniae
por: Kim, Jong Hun, et al.
Publicado: (2019)

Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy
por: Park, Hyunkyung, et al.
Publicado: (2019)

Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation
por: Zilberberg, Marya D, et al.
Publicado: (2009)

Micafungin induced apoptosis in Candida parapsilosis independent of its susceptibility to micafungin
por: Shirazi, Fazal, et al.
Publicado: (2015)

Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
por: Reboli, Annette C, et al.
Publicado: (2011)

Clinical significance of antinuclear antibody positivity in patients with severe coronavirus disease 2019
por: Park, Soo Hyun, et al.
Publicado: (2023)

1509. Clinical Features and Outcomes of COVID-19 in People Living with HIV in South Korea: a Nationwide Population-based Cohort Study
por: Yoon, Young Kyung, et al.
Publicado: (2023)

Anidulafungin in the treatment of invasive fungal infections
por: Sabol, Kathryn, et al.
Publicado: (2008)

Anidulafungin and its role in candida infections
por: Cappelletty, Diane M, et al.
Publicado: (2009)

Pharmacokinetics of anidulafungin during albumin dialysis
por: Aguilar, Gerardo, et al.
Publicado: (2014)

Does Weight Impact Anidulafungin Pharmacokinetics?
por: Lempers, Vincent J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j26hl8b66rjdhjk9ajfrmbr9gn